Response to growth hormone treatment in patients with sufficient secretion

There are situations of short stature, with a normal stimulus test for GH, but decreased nocturnal secretion in which there could be a benefit with GH treatment. To assess adult height and height gain in patients with neurosecretory dysfunction diagnosis treated with growth hormone. Longitudinal, retrospective and observational study including 61 patients treated with growth hormone after diagnosis of neurosecretory dysfunction who have already reached adult height. Variables such as adult height gain, growth rate, growth prognosis variation and IGF-I and IGFBP-3 were evaluated. Variables related to a good response in the first year have also been calculated, using the Index of responsiveness (IoR). GH treatment produces an improvement in growth rate and height, observing an increase in adult height with respect to initial height of 1.15±0.60 SD, height with respect to genetic height of -0.015±0.62 SD and adult height with respect to the initial growth prognosis 0,74±1,13 DE. The IoR in the first year is associated with a greater increase in height in the first year (p=0.000), with a greater adult height (p=0.000) and with a greater gain in adult height compared to its initial height (p=0.039). Patients with growth delay due to neurosecretory dysfunction of GH show a good response to treatment with rhGH, observing a significant height gain in their genetic size and improving their initial growth prognosis. Existen situaciones de talla baja, con test de estímulo para GH normal, pero secreción nocturna disminuida en la que podría existir un beneficio con el tratamiento con GH. Evaluar la talla adulta y la ganancia de talla en pacientes con diagnóstico de disfunción neurosecretora tratados con hormona del crecimiento. Estudio longitudinal, retrospectivo y observacional con 61 pacientes tratados con GH tras diagnóstico de disfunción neurosecretora que han alcanzado la talla adulta. Se evaluaron variables como la ganancia de talla adulta, la velocidad de crecimiento, la variación del pronóstico de crecimiento y la evolución de IGF-I e IGFBP-3. También han sido calculadas variables de buena respuesta en el primer año, mediante el uso del Index of responsiveness (IoR). Hubo una mejoría en la talla y en la velocidad de crecimiento, observándose un incremento de talla adulta respecto a talla inicial de 1,15±0,60DE, talla respecto a talla genética de -0,015±0,62DE y talla adulta respecto a pronóstico de crecimiento inicial 0,74±1,13 DE. El IoR en el primer año se as